VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Classical swine fever virus vaccine VAC-E2
Vaccine Information
  • Vaccine Name: Classical swine fever virus vaccine VAC-E2
  • Target Pathogen: Classical swine fever virus
  • Target Disease: Classical swine fever, hog cholera
  • Vaccine Ontology ID: VO_0011508
  • Type: Recombinant vector vaccine
  • Status: Research
  • Antigen: Classical swine fever virus E2
  • E2 gene engineering:
    • Type: Recombinant vector construction
    • Description: A 1.5-kbp DNA fragment (representing nucleotides 2433 to 3971 of CSFV Alfort Tu¨bingen) isolated from clone pHCK11 by NheI-HpaI digestion was ligated into plasmid pBR02-16/4. The resulting construct contained the nucleotide sequences for CSFV E2 and PRV-SP. Isolation of the PRV-SP E2 sequence and introduction into vector pGS62 gave rise to pGS62-E2 (König et al., 1995).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intradermal injection (i.d.)
Host Response

Pig Response

  • Vaccination Protocol: Pigs were vaccinated with a single dose of VVR (VAC-E0 or VAC-E2) or control strain VAC-WR by three different routes simultaneously (intradermally, intraperitoneally, and intravenously). A total of 5 x 10^7 PFU of VVR was given by each route. Clinical reactions after vaccination were monitored by daily examination (König et al., 1995).
  • Challenge Protocol: The pigs were challenged intranasally 5 weeks after immunization with 2 x 10^7 50% tissue culture infective doses of CSFV Alfort Tu¨bingen. Clinical symptoms were monitored daily. Blood samples were taken at days 5 and 12 postinfection (p.i.) and at the slaughter of the animals (days 12 to 27 p.i.) (König et al., 1995).
  • Efficacy: Swine vaccinated with VVR expressing E0 and/or E2 resisted a lethal challenge infection with CSFV. Glycoprotein E0 represents a second determinant for the induction of protective immunity against classical swine fever (König et al., 1995).
References
König et al., 1995: König M, Lengsfeld T, Pauly T, Stark R, Thiel HJ. Classical swine fever virus: independent induction of protective immunity by two structural glycoproteins. Journal of virology. 1995; 69(10); 6479-6486. [PubMed: 7666549].